Metformin	Placebo	Improvement of diastolic function echocardiographic markers 	1816	1925	In addition, metformin did not improve any of the individual echocardiographic markers of diastolic function.
Metformin	Placebo	Presence of diastolic dysfunction during hospitalization	1545	1691	Diastolic dysfunction was present in 11 (9%) of patients on metformin and 11 (9%) patients on placebo treatment (P = 0.98) during hospitalization.
Metformin	Placebo	Presence of diastolic dysfunction after 4 months 	1692	1815	After 4 months 22 (19%) of patients with metformin and 18 (15%) patients with placebo (P = 0.47) had diastolic dysfunction.
Metformin	Placebo	Improvement of diastolic function echocardiographic markers 	1829	1925	metformin did not improve any of the individual echocardiographic markers of diastolic function.
Metformin	Placebo	Measurements of cardiac structure and function during hospitalization	13273	13423	During hospitalization, measurements of cardiac structure and function for patients treated with metformin (n = 118) or placebo (n = 119) were similar
Metformin	Placebo	Measurements of cardiac structure and function during hospitalization	13273	13434	During hospitalization, measurements of cardiac structure and function for patients treated with metformin (n = 118) or placebo (n = 119) were similar (Table 2).
Metformin	Placebo	Presence of diastolic dysfunction after 4 months 	1692	1814	After 4 months 22 (19%) of patients with metformin and 18 (15%) patients with placebo (P = 0.47) had diastolic dysfunction
